SeaStar Medical Issued U.S. Patent No. 11,866,730 With Broad Claims Covering Use Of Selective Cytopheretic Device For Subjects With Inflammatory Conditions And To Process Activated Leukocytes And Platelets
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical has been granted U.S. Patent No. 11,866,730, which encompasses methods for treating inflammatory conditions using its Selective Cytopheretic Device (SCD) cartridges. The patent specifies the use of SCD cartridges to extracorporeally sequester activated leukocytes and/or platelets, modulating their inflammatory activity without adversely affecting the healing process by maintaining appropriate cell counts. The patent details the required ratios of surface area to inner volume of the SCD cartridge for effective treatment.
January 09, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical's new patent for SCD cartridges may enhance the company's product portfolio and potentially lead to increased market share and revenue in the medical device sector.
The issuance of a new patent generally strengthens a company's intellectual property portfolio, potentially leading to competitive advantages, increased market share, and revenue growth. As SeaStar Medical secures this patent, it may see a positive impact on its stock price in the short term due to investor optimism about the company's enhanced product offerings and future market potential.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80